Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome
Abstract
OBJECTIVE: To determine anti-beta2 glycoprotein-I (anti-beta2GPI) and anti-prothrombin (anti-ProT) antibody levels, and the IgG subclass distribution of anti-beta2GPI antibodies, in serial samples from patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) having initial or recurrent thrombotic/neurological (T/N) events during the study period. To investigate the correlations between these antibodies and beta2GPI antigen, anticardiolipin antibody (aCL), anti-double-stranded (ds) DNA, C3 levels and disease activity. METHODS: Fifty serum samples were identified from seven patients with SLE who had had T/N events during the follow-up from a cohort under long-term follow-up. IgG anti-beta2GPI, anti-ProT, aCL, IgG subclasses of anti-beta2GPI and beta2GPI antigen levels were determined by ELISA. Corresponding disease activity [British Isles Lupus Assessment Group (BILAG)], anti-dsDNA and C3 levels were compared. RESULTS: IgG anti-beta2GPI antibody levels were elevated in six of the patients before and after the T/N events with less marked fluctuations than aCL antibody levels. The predominant subclass of anti-beta2GPI antibodies was IgG2 before and after the T/N events. IgG anti-ProT antibodies were negative in all cases. There was a significant but weak correlation between anti-beta2GPI and aCL antibodies. No correlation was found between disease activity and IgG anti-beta2GPI antibody and beta2GPI antigen levels. There were fluctuations in beta2GPI antigen levels and a trend to increase after T/N events was observed in some patients. CONCLUSION: Most of the patients with a T/N event during the study period had IgG anti-beta2GPI, but not IgG anti-ProT antibodies. Many IgG aCL-negative samples were found to have IgG anti-beta2GPI activity during the follow-up period. The predominant subclass of IgG anti-beta2GPI was IgG2, which may have importance in the pathogenesis of APS. beta2GPI antigen levels were found to be increased in some patients with SLE after T/N events. IgG anti-beta2GPI antibodies may be used as an adjunctive marker of future T/N events in patients with SLE and APS with aCL antibodies and lupus anticoagulant.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In SLE, aPL often fluctuate and are often at low or moderate titres, which still confer risk.
“However, in SLE, aPL often fluctuate and are often at low or moderate titres, which still confer risk [41–43].”
From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [43]
Cited by
Sorted by citations
Complement and coagulation: strangers or partners in crime?
Markiewski, M., Nilsson, B., Ekdahl, K., Mollnes, T., & Lambris, J. D. (2007) · Trends in immunology · doi:10.1016/j.it.2007.02.006 · Cited by 664 · see citing works
Sciascia, S., Sanna, G., Murru, V., Roccatello, D., Khamashta, M. A., & Bertolaccini, M. L. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-06-0509 · Cited by 253 · see citing works
Cuadrado, M. J., Khamashta, M. A., Ballesteros, A., et al. (2000) · Medicine · doi:10.1097/00005792-200001000-00006 · Cited by 169 · see citing works
Predictive value of autoantibodies for activity of systemic lupus erythematosus
Reveille, J. D. (2004) · Lupus · doi:10.1191/0961203303lu1015oa · Cited by 120 · see citing works
Antiprothrombin antibodies detected in two different assay systems
Atsumi, T., Koike, T., Hughes, G. R. V., Khamashta, M. A., & Bertolaccini, M. L. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-06-0382 · Cited by 113 · see citing works
Complement, inflammation and thrombosis
Rawish, E., Sauter, M., Sauter, M., Nording, H., & Langer, H. F. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15476 · Cited by 108 · see citing works
Which are the Best Biological Markers of the Antiphospholipid Syndrome?
Carreras, L. O., Forastiero, R. R., & Martinuzzo, M. E. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0401 · Cited by 78 · see citing works
Martinez-Berriotxoa, A., Ruiz-Irastorza, G., Egurbide, M.-V., Garmendia, M., Gabriel Erdozain, J., Villar, I., & Aguirre, C. (2007) · Lupus · doi:10.1177/0961203307083316 · Cited by 77 · see citing works
Specificities, properties, and clinical significance of antiprothrombin antibodies
Amengual, O., Atsumi, T., & Koike, T. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10831 · Cited by 66 · see citing works
Sorice, M., Pittoni, V., Griggi, T., et al. (2000) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2000.01206.x · Cited by 52 · see citing works
Sastre‐Garriga, J., Reverter, J. C., Font, J., et al. (2001) · Annals of Neurology · doi:10.1002/ana.81 · Cited by 44 · see citing works
Antiprothrombin antibodies—are they worth assaying?
Atsumi, T., Amengual, O., Yasuda, S., et al. (2004) · Thrombosis Research · doi:10.1016/j.thromres.2004.08.024 · Cited by 42 · see citing works
Antinuclear antibodies: cause of disease or caused by disease?
Smeenk, R. J. T. (2000) · British journal of rheumatology · doi:10.1093/rheumatology/39.6.581 · Cited by 41 · see citing works
Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus
Demir, S., Li, J., Magder, L. S., & Petri, M. (2021) · Rheumatology · doi:10.1093/rheumatology/keaa857 · Cited by 38 · see citing works
čučnik, Š., Ambrožič, A., Božič, B., et al. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.111 · Cited by 35 · see citing works
Pittoni, V., Ravirajan, C. T., Donohoe, S., et al. (2000) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2000.01161.x · Cited by 35 · see citing works
Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling
Kölm, R., Schaller, M. M., Roumenina, L. T., Niemiec, I., Hovinga, J. A. K., Khanicheh, E., Kaufmann, B. A., Hopfer, H., & Trendelenburg, M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501876 · Cited by 33 · see citing works
Antiprothombin antibodies and the diagnosis of antiphospholipid syndrome
Amengual, O., Atsumi, T., & Koike, T. (2004) · Clinical Immunology · doi:10.1016/j.clim.2004.02.013 · Cited by 28 · see citing works
Anti-β2-glycoprotein I in Sjogren’s syndrome is associated with parkinsonism
Hassin‐Baer, S., Levy, Y., Langevitz, P., et al. (2006) · Clinical Rheumatology · doi:10.1007/s10067-006-0398-8 · Cited by 25 · see citing works
Szodoray, P., Tarr, T., Tumpek, J., et al. (2009) · Autoimmunity · doi:10.1080/08916930902882731 · Cited by 24 · see citing works
Zhang, C., Ren, L., Gao, F., Mu, F.-Y., You, Y., & Liu, Y. (2011) · Clinical Rheumatology · doi:10.1007/s10067-011-1698-1 · Cited by 22 · see citing works
Lupus Registries: Evolution and Challenges
Lu, L., Wallace, D. J., Navarra, S., & Weisman, M. H. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.08.009 · Cited by 21 · see citing works
Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia
Öztürk, M. A., Haznedaroğlu, İ. C., Turgut, M., & Göker, H. (2004) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/107602960401000201 · Cited by 19 · see citing works
Autoantibodies Associated with Rheumatic Diseases
Griesmacher, A., & Peichl, P. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.031 · Cited by 19 · see citing works
Antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus
Palomo, I. F., Pereira, J. I., Alarcón, M. A., Larrain, A. M., Pinochet, C., Vásquez, M., Vélez, M. T., Leon, M., Espinola, R. G., & Pierangeli, S. S. (2002) · Journal of Laboratory and Clinical Medicine · doi:10.1067/mlc.2002.128467 · Cited by 17 · see citing works
Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers
Chaturvedi, S., & McCrae, K. R. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0668-2 · Cited by 16 · see citing works
Frodlund, M., Walhelm, T., Dahle, C., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.646846 · Cited by 14 · see citing works
Bondanza, A., Sabbadini, M. G., Pellegatta, F., et al. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0449 · Cited by 16 · see citing works
Čučnik, S., Božič, B., Kveder, T., et al. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1361.055 · Cited by 13 · see citing works
Deciphering the clinical significance of longitudinal antiphospholipid antibody titers
Chighizola, C. B., Willis, R., Maioli, G., Sciascia, S., Andréoli, L., Amengual, O., Radin, M., Gerosa, M., Atsumi, T., de Jesús, G. R., et al. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103510 · Cited by 15 · see citing works
Al-Balushi, M. S., Hasson, S. S., Said, E. A., Al-Busaidi, J. Z., Al-Daihani, M. S., Othman, M. S., Sallam, T. A., Idris, M. A., Al-Kalbani, M., Woodhouse, N., et al. (2014) · Sultan Qaboos University medical journal · doi:10.18295/2075-0528.1622 · Cited by 10 · see citing works
Davies, M. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.4.395 · Cited by 10 · see citing works
Ong, S. G., Cheng, H. M., Soon, S. C., et al. (2002) · Clinical Rheumatology · doi:10.1007/s100670200102 · Cited by 6 · see citing works
Şahin, M., Düzgün, N., Tunç, Ş. E., et al. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2006.12.013 · Cited by 5 · see citing works
Anti-cardiolipin/β-2 glycoprotein activities co-exist on human anti-DNA antibody light chains
Kumar, S., Nagl, S., Kalsi, J., et al. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00225-6 · Cited by 5 · see citing works
Interpreting Female Agency and Responsibility in the Miller's Tale and the Merchant's Tale
Parry, J. D. (2001) · Philological quarterly · Cited by 4 · see citing works
Xie, R., Li, L., Chen, L., et al. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2829 · Cited by 3 · see citing works
Structure and function of autoantibodies and their role in autoimmune rheumatic diseases
Rahman, A., & Giles, I. (2006) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2.2.225 · Cited by 3 · see citing works
Kumar, S., Nagl, S., Kalsi, J., et al. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.012 · Cited by 3 · see citing works
Božič, B., Čučnik, S., Gašperšič, N., et al. (2010) · PubMed · Cited by 2 · see citing works
Role of anti-prothrombin in antiphospholipid syndrome
Cinquini, M., Vianelli, M., Allegri, F., Cattaneo, R., Balestrieri, G., & Tincani, A. (2011) · Reumatismo · doi:10.4081/reumatismo.2002.243
Síndroma antifosfolípido primária catastrófica.
Casanova, P., Baptista, J. P., Andrade, M. J., Martins, P., Sousa, J. P. A., Fernandes, V., Simões, A., Gonçalves, J. S., Costa, J., Rebelo, A., et al. (2003) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.20344/amp.1179
- Authors
- Inanc, M.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-10-01
- Volume
- 37
- Issue
- 10
- Pages
- 1089-1094
- ISSN
- 0263-7103 (ISSN-L)
- 1460-2172
- OpenAlex
- W4322697217
- Cited by
- 42
- References
- 0
- Citations by year
- 2024: 1 · 2021: 2 · 2020: 1 · 2017: 1 · 2016: 2 · 2014: 1 · 2013: 1
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- British journal of rheumatology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- PubMed
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
- Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
- Keywords
- anti-beta2-glycoprotein I antibodies, anti-prothrombin antibodies, anticardiolipin antibodies, antiphospholipid syndrome, systemic lupus erythematosus, thrombotic complications, neurological events, IgG subclasses, disease activity, lupus anticoagulant
- MeSH terms
- Adult, Antibodies, Antinuclear, Cerebrovascular Disorders, Complement C3, Enzyme-Linked Immunosorbent Assay, Female, Glycoproteins, Humans, Immunoglobulin G, Immunoglobulin M, Longitudinal Studies, Lupus Erythematosus, Systemic, Middle Aged, Prothrombin, Thrombosis, Antiphospholipid Syndrome, Antibodies, Anticardiolipin, beta 2-Glycoprotein I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
